Mochida Pharmaceutical Co.,Ltd. [4534.T]
TOKYO, Mar 30 (Pulse News Wire) – Mochida Pharmaceutical CO.,LTD. (4534.T) announced today that its board of directors approved the acquisition of manufacturing and sales rights for the furosemide tablet “Uris” from Fuji Yakuhin Co., Ltd.
The agreement was finalized, and the asset transfer is scheduled to take place on June 30, 2026. The furosemide tablet, used for treating gout and hyperuricemia, was developed by Fuji Yakuhin and received regulatory approval in January 2026. Since May 2026, Mochida Pharmaceutical has handled distribution while both companies jointly conducted informational activities. With this acquisition, Mochida Pharmaceutical will become the sole manufacturer and distributor of the product. In the fiscal year ending March 2025, the total revenue generated from the furosemide tablet amounted to approximately ¥4.600 billion.
The transaction price for the assets, which are expected to be recorded as intangible fixed assets, is set at ¥13.50 billion. Fuji Yakuhin, headquartered in Saitama City, was established in April 1954 and engages in pharmaceutical manufacturing and medical drug sales. The company's capital stands at ¥100 million. Looking ahead, the asset transfer is planned to occur in the next fiscal year, meaning there will be no impact on the consolidated performance for the fiscal year ending March 2026. Detailed forecasts for the fiscal year ending March 2027 will be disclosed during the earnings release in May 2026.
🟢 Confidence: High AI-translated content.